HSCT vs DMT : What the Global Evidence actually shows — And Why the Answer May Surprise You

Here is something worth sitting with for a moment. Millions of people living with Multiple Sclerosis take their medication faithfully — every day, every injection, every infusion — trusting that modern disease-modifying therapies are the best medicine has to offer. Interferons. Natalizumab. Ocrelizumab. Cladribine. These drugs are sophisticated, expensive, and — let us be honest — only partially effective. They slow things down. They reduce relapses. But they do not stop the disease. They never have.

HSCT — Hematopoietic Stem Cell Transplantation — does something categorically different. It does not slow the immune system’s assault on the nervous system. It ends it. A single course of high-dose chemotherapy eliminates the dysfunctional immune cells responsible for the autoimmune attack, and the patient’s own harvested stem cells are reinfused to rebuild a new, healthy immune system — one that has, in effect, forgotten that it was supposed to destroy myelin. One treatment. Potentially, a lifetime of remission.

But which approach actually wins when you stack the global evidence side by side? And what happens when you look beyond MS — at Scleroderma, CIDP, Lupus, Myasthenia Gravis ? The data is in. It is substantial. And it tells a story that every MS patient deserves to hear.

Two Treatments. – Two Entirely Different Philosophies.

This distinction matters more than most people realise, so let us be precise about it.

DMTs MANAGE. They suppress or modulate the immune system — reducing the frequency and ferocity of attacks on the myelin sheath. The underlying malfunction, however, continues unabated. The immune system is not fixed; it is restrained. Stop the medication and, in the majority of cases, disease activity resurges. Sometimes violently. Patients are, in essence, tethered to their therapy indefinitely, their disease held at arm’s length but never truly defeated.

HSCT RESETS. The procedure ablates the autoreactive lymphocytes — the cells at the root of the immune system’s catastrophic self-attack — using chemotherapy, then reconstitutes the immune system entirely from the patient’s own previously collected stem cells. The regenerated immune system, emerging into a non-inflammatory environment devoid of the “danger signals” that originally triggered autoimmunity, no longer identifies myelin as an enemy. The ambition here is not management. It is elimination.

The MIST Trial: The Most Important Data You Have Probably Never Been Shown

In 2019, the Journal of the American Medical Association published the results of the MIST trial — the Multiple Sclerosis International Stem Cell Transplant randomised clinical trial, led by Dr. Richard K. Burt of Northwestern University Feinberg School of Medicine. It was, and remains, the only properly randomised head-to-head comparison of HSCT against continuing DMT ever conducted.

The design was rigorous. 110 patients with relapsing-remitting MS — all of whom had experienced at least two relapses in the previous year despite being on DMT — were randomised equally. Fifty-five received HSCT using a non-myeloablative cyclophosphamide plus ATG conditioning regimen. Fifty-five continued or escalated to a different, higher-efficacy DMT. The trial ran across four international centres on three continents from 2005 to 2016. These were real patients, with real disease burden, evaluated under real clinical conditions.

What happened at five years?

• Disease progression — HSCT group: 9.71%. Just under one in ten patients experienced worsening disability over five years.
• Disease progression — DMT group: 75.3%. Three in every four patients worsened. The median time to progression was 24 months — they were deteriorating within two years of the trial beginning.
• The hazard ratio was 0.07. Translation: patients treated with HSCT were 93% less likely to experience disease progression than those who stayed on DMT.
• EDSS scores — HSCT group: Improved. Mean scores dropped from 3.38 to 2.36 in the first year. Disability was not just halted — it was reversing.
• EDSS scores — DMT group: Worsened. Mean scores rose from 3.31 to 3.98 in the same period. The standard-of-care arm was failing while the experimental arm was succeeding.
• Relapses: One. A single relapse across the entire HSCT arm. The DMT arm recorded 39.
• No deaths. No grade 4 non-haematopoietic toxicities in the HSCT group. Safety was not the problem everyone feared.

NEDA-3: The Metric That Exposes Everything

NEDA-3 — No Evidence of Disease Activity, composite measure three — is the most demanding benchmark in MS medicine. To achieve it, a patient must simultaneously have zero relapses, zero new MRI lesions, and zero disability progression. It represents, in short, the goal every MS patient hopes for: a life without disease activity.

Here is what years of published data tells us about how often different therapies achieve it:

2. Norway Long-Term Follow-Up Study (2024) — 70-Month Outcomes

Published in the Multiple Sclerosis Journal in 2024, this national study from Norway followed 29 patients with aggressive RRMS — all of whom had failed two or more DMTs — for an average of 70 months (nearly 6 years) after HSCT. Its findings are striking:

• 69% achieved NEDA-3 status (No Evidence of Disease Activity — no relapses, no MRI progression, no disability worsening).
• 83% were completely relapse-free throughout the entire follow-up period.
• 79% showed no new MRI activity — meaning no new lesions detected for years after a single treatment.
• 90% were free of disability progression.
• Work participation transformed: before HSCT, only 1 patient (3%) worked full time. By year 5, 52% had returned to full-time employment.

This last finding deserves emphasis. HSCT for MS is not simply a medical treatment — it is a socioeconomic transformation. Patients who were unable to work because of their disease returned to productive, independent lives.

3. The Neurology Journal 11-15 Year Follow-Up — The Longest Followup Study Ever

Perhaps the most remarkable evidence comes from one of the longest follow-up studies ever conducted on HSCT for MS.Patients were tracked for up to 15 years after treatment.

• Disease progression-free survival at 15 years was 44% for patients with active CNS lesions at baseline — a remarkable result for a single one-time treatment.
• Improvements in EDSS scores of 0.5 to 5.5 points were observed in 16 patients, and in 9 of these, scores never worsened beyond their pre-transplant baseline.
• Sustained suppression of MRI disease activity was observed across the decade-long follow-up period.

For a disease historically defined by gradual deterioration, this represents a profound shift.: no DMT currently available achieves this level of sustained disease control over such a prolonged time horizon with a single course of treatment.

4. Swedish 5-Year Data — 87% Relapse-Free Survival

Evidence from Sweden further reinforces the global pattern. Prospective study of 41 patients with aggressive MS documented the following outcomes at 5 years post-HSCT:

• 87% relapse-free survival rate at 5 years.
• 85% MRI event-free survival — no new lesions in 85 out of 100 patients after 5 years.
• 77% free of EDSS progression — three quarters of patients showed no worsening of disability.

HSCT Vs DMT: A 10-Year Comparison that Speaks for itself.

The landmark JAMA randomised clinical trial by Dr. Richard K. Burt and colleagues directly compared HSCT against continuing DMT in 110 RRMS patients. The results at 5 years were unambiguous:

• HSCT group: Only 9.71% showed disease progression at 5 years.
• DMT group: 61.7% experienced disease progression within the same timeframe (median time to progression just 24 months).
• EDSS improved by an average of 1.02 points in the HSCT group. In the DMT group, EDSS worsened by 0.67 points.
• The hazard ratio for progression in the HSCT group versus DMT was 0.07 — meaning patients on HSCT were 93% less likely to experience disease progression.

This trial, combined with the observational long-term data, has prompted ECTRIMS (European Committee for Treatment and Research in MS) and the EBMT to publish updated 2025 guidelines recommending HSCT as a treatment option for patients with aggressive MS.

Who Benefits Most from HSCT? What the Data Reveals

The long-term research consistently identifies a profile of patients who achieve the best outcomes from HSCT:

• Relapsing-Remitting MS (RRMS): The strongest evidence base. RRMS patients consistently show the best long-term response, with 69-87% maintaining NEDA status at 5-7 years.
• Younger patients: Age at treatment is one of the strongest predictors of long-term success. Earlier intervention yields better immune reconstitution.
• Active inflammatory disease: Patients with gadolinium-enhancing lesions on MRI (indicating active inflammation) show dramatically better outcomes, with progression-free survival at 15 years of 44% vs 10% in those without active lesions.
• Lower baseline EDSS: Patients with less accumulated disability achieve greater neurological improvement. This is the core argument for not delaying HSCT.
• Fewer prior DMTs: Patients treated with HSCT before exhausting multiple lines of therapy achieve better outcomes than those treated as a last resort.

HSCT Hospital India accepts patients across RRMS, SPMS, PPMS, and progressive forms of MS, as well as those with other autoimmune conditions including CIDP, Myasthenia Gravis, and SLE. All patients undergo a detailed multidisciplinary evaluation to determine suitability.

Understanding NEDA No Evidence of Disease Activity: The Gold Standard for Measuring HSCT Success

NEDA-3 — No Evidence of Disease Activity — is the highest benchmark in MS treatment. It means a patient has zero relapses, zero new MRI lesions, and zero disability progression. It is remarkably difficult to achieve with conventional DMTs, with studies showing only 7.9% of DMT-treated patients maintaining NEDA at 7 years.

HSCT consistently achieves NEDA-3 in 65-83% of patients in the first five years — an approximately ten-fold improvement over the best conventional therapies. This is not incremental progress. It represents a fundamentally different category of treatment outcome.

1. Muraro PA et al. Long-term outcomes after autologous HSCT for MS. JAMA Neurology. 2017;74(4):459–469.
2. Kvistad CE et al. Autologous HSCT for MS: Long-term follow-up data from Norway. Multiple Sclerosis Journal. 2024. doi:10.1177/13524585241231665.
3. Burt RK et al. Effect of nonmyeloablative HSCT vs continued DMT on disease progression in RRMS. JAMA. 2019;321(2):165–174.
4. Mancardi GL et al. Long-term results of HSCT for MS. Neurology. 2011. doi:10.1212/WNL.0b013e318211c537.
5. Zephir H et al. ECTRIMS/EBMT recommendations for AHSCT for MS and NMOSD. Nature Reviews Neurology. 2025;21(3):140–158.

Why Choose HSCT Hospital India for Your Long-Term MS Treatment

The research is clear: outcomes are best at high-volume, accredited centres with experienced transplant teams. Clinical outcomes are strongly linked to experience and facility standards. HSCT Hospital India has been delivering HSCT for MS since 2016 at #1 JCI-USA accredited World Class Hospital In India .

• Treatment based on the Dr. Richard Burt non-myeloablative protocol— Burt — the same protocol that produced the landmark JAMA trial results.
  
• JCI-USA Accredited, NABH & NABL certified — the highest standards of patient safety and clinical governance.
• 1,500+ patients treated from over 30 countries across Europe, North America, and Australia. Watch video testimonials Click here
• All-inclusive 30-day in-hospital package at $30,000 USD — the most transparent and affordable pricing of any accredited HSCT centre globally. Check out HSCT package details Click here
• HEPA-filtered private rooms with triple-level air filtration — no outside hospital stays, eliminating infection risk during the critical engraftment phase.